Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer by Marini, Cecilia et al.
1Scientific RepoRts | 6:19569 | DOI: 10.1038/srep19569
www.nature.com/scientificreports
Divergent targets of glycolysis and 
oxidative phosphorylation result 
in additive effects of metformin 
and starvation in colon and breast 
cancer
Cecilia Marini1,*, Giovanna Bianchi2,*, Ambra Buschiazzo3, Silvia Ravera4, Roberto Martella2, 
Gianluca Bottoni3, Andrea Petretto5, Laura Emionite6, Elena Monteverde3, Selene Capitanio3, 
Elvira Inglese5, Marina Fabbi7, Francesca Bongioanni3, Lucia Garaboldi3, Paolo Bruzzi8, 
Anna Maria Orengo3, Lizzia Raffaghello2 & Gianmario Sambuceti3
Emerging evidence demonstrates that targeting energy metabolism is a promising strategy to 
fight cancer. Here we show that combining metformin and short-term starvation markedly impairs 
metabolism and growth of colon and breast cancer. The impairment in glycolytic flux caused 
by starvation is enhanced by metformin through its interference with hexokinase II activity, as 
documented by measurement of 18F-fluorodeoxyglycose uptake. Oxidative phosphorylation is 
additively compromised by combined treatment: metformin virtually abolishes Complex I function; 
starvation determines an uncoupled status of OXPHOS and amplifies the activity of respiratory 
Complexes II and IV thus combining a massive ATP depletion with a significant increase in reactive 
oxygen species. More importantly, the combined treatment profoundly impairs cancer glucose 
metabolism and virtually abolishes lesion growth in experimental models of breast and colon 
carcinoma. Our results strongly suggest that energy metabolism is a promising target to reduce cancer 
progression.
Cancer energy metabolism is regulated to support high-energy demand and increased biosynthesis of macro-
molecules for a rapidly growing biomass. As in most tissues with high proliferative activity, this metabolic pat-
tern commonly implies a high glycolytic flux facing relatively low rates of oxidative phosphorylation (OXPHOS) 
regardless an adequate tissue oxygen tension. This phenomenon known as “Warburg effect” is particularly func-
tional for cancer eventually slowing OXPHOS whose generation of reactive oxygen species (ROS) would inevita-
bly hamper cellular redox status and thus DNA replication1.
Due to these features, this metabolic reprogramming has to face the relatively low efficient ATP production 
allowed by glucose conversion to lactate. This limitation is most often overcome by an enhanced expression of 
glucose transporters increasing glycolytic flux as to enable cancer to rapidly deplete glucose from the surrounding 
tissues2. Nevertheless, this task is often difficult to achieve in the hypo-vascular microenvironment of a rapidly 
growing mass and contributes to the frequent occurrence of necrotic core in large cancer lesions3.
According to this consideration, targeting energy metabolism represents a promising tool in anti-cancer ther-
apy. In this line, short-term starvation (STS) has been found to profoundly impair cancer growth at least partially 
by down-regulating glycolytic flux and increasing cell dependency on OXPHOS4. This metabolic reprogramming 
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inevitably increases oxygen consumption rate (OCR) and ROS production5,6 whose toxic consequences are more 
pronounced for proliferating cancer cells with respect to normal tissues7. However, these effects are intrinsi-
cally transient and more severe impairments in energy metabolism are required to prevent growth rebound after 
re-feeding8.
Recent evidence indicates that metformin (MTF) – the most widely used drug in treatment of type 2 diabe-
tes – might represent a suitable tool to this purpose. On one side, drug-induced reduction in hepatic glucone-
ogenesis and glucose release in the bloodstream9–11 should limit liver buffer function and amplify the decrease 
in serum glucose level during periods of reduced nutrients intake. On the other hand, MTF has been shown to 
hamper cancer fuelling via a direct inhibition of mitochondrial respiratory Complex I that might complement 
energy depletion caused by STS12,13. In agreement with this hypothesis, several experimental studies documented 
a significant reduction in ATP synthesis in MTF-treated cancer models resulting in reduced cell proliferation up 
to cell death14–16. Vice versa, the low glucose availability caused by STS would prevent the increase in glycolytic 
flux described in cancer cells in response to OXPHOS inhibition by MTF through its interference with Complex 
I function12,17.
The present study was designed to verify the potential of combining MTF and STS in reducing cancer growth 
in murine models of colon (CT26) and breast (4T1) carcinoma. This hypothesis was first verified in vivo by 
imaging studies documenting the systemic reaction to the metabolic perturbation and the additive interference 
of MTF and STS on metabolism and growth of both cancer models. Thereafter, the underlying mechanisms were 
evaluated in cell cultures in which the combined treatment coupled a profound and simultaneous alteration in 
glycolytic flux and OXPHOS, eventually combining oxidative damage and ATP depletion as to impair cell viabil-
ity and proliferation.
Results
Metformin and starvation affect cancer growth and glucose metabolism in vivo models. In vivo 
experiments confirmed the hypothesis that MTF, STS and their combination remarkably reduce cancer growth. 
As a first step, toxic profile of STS + MTF was verified in twelve animals submitted to the inoculation of 200 000 
CT26 cells and followed for 15 days without any other manoeuvre with (n = 6) or without (n = 6) combined treat-
ment. For imaging study, each cancer model was subcutaneously implanted in four mice groups (control n = 6, 
STS n = 6, MTF n = 6, and merged treatment n = 6) accounting for a total of 48 studied animals. The studies were 
completed in all animals and no side effects occurred at the drug dosage used. Body weight was not modified by 
MTF while it showed a transient decrease at the end of STS regardless drug treatment. On the contrary, serum 
glucose concentration was not affected by MTF, it was slightly and not significantly reduced by STS and reached 
its lowest values in mice exposed to the combined treatment before both imaging studies (Supplementary Table 
1).
Both tumour models became visible and palpable at day #5 after subcutaneous implantation in control ani-
mals. At subsequent monitoring, growth rate was higher for CT26 (Fig. 1A) with respect to 4T1 (Fig. 1B) lesions 
while it was comparably reduced by MTF. Similarly, first STS application stopped cancer expansion that, however, 
reaccelerated in the re-feeding period in both models. This rebound phase was particularly evident in CT26 
animals (Fig. 1A) while it was largely smoothed in 4T1 ones (Fig. 1B). In both experiments, repeated STS again 
interrupted lesion growth confirming the transient nature of STS effect.
Despite these differential responses, combining MTF and STS virtually flattened tumour growth throughout 
the study in both cancer types. In fact, volume reduction with respect to control animals reached the statistical 
significance already at day #9 and became progressively more evident up to experiment termination at day #14, 
both in CT26 mice (63 ± 50 mm3 vs 315 ± 180 mm3, respectively, p < 0.001) and in 4T1 ones (63 ± 20 mm3 vs 
240 ± 80 mm3, respectively, p < 0.001) (Fig. 1A,B). No significant interaction between the two treatments could 
be documented (Supplementary Figure 1A). Treatment effect on tumour growth (Supplementary Figure 1B) was 
confirmed by the analysis of the six animals not submitted to radionuclide imaging after CT26 inoculum.
Dynamic microPET scanning with 18F-fluoro-deoxyglucose (FDG) documented that tumour metabolic 
response preceded the growth reduction: at day #7, both MTF and STS significantly reduced lesion glucose con-
sumption (MRGlu) in both CT26 (Fig. 1C) and 4T1 (Fig. 1D) models. This response persisted for the whole 
experiment particularly in the presence of STS. At both imaging times (day #7 and #14), synergism analysis 
reported a negative interaction between the two interventions, suggesting that both MTF and STS actually acted 
on the same metabolic pathways (Supplementary Figure 1C-D). A similar consideration also applied to total 
cancer glucose consumption that mostly decreased in mice exposed to the combined treatment in both cancer 
models (Fig. 1E,F) again with a negative interaction between the two treatments (Supplementary Figure1 E-F).
Intriguingly, the large disparity in tumour metabolism observed at parametric maps of glucose consump-
tion (Fig. 2), was markedly less evident in conventional images in which the high variability of tracer reten-
tion smoothed the differences in standardized values of tracer uptake (SUV) among the tested protocols 
(Supplementary Figure 1G).
Direct effect of metformihn and starvation on cancer glucose consumption. To rule out the con-
founding effect of systemic feedback mechanisms, we evaluated MTF and STS effect on glucose consumption by 
measuring FDG uptake in cultured cells using the same factorial experimental design of the in vivo study. In can-
cer cells, MTF decreased glucose consumption in a dose dependent fashion. Actually, this effect was slightly dif-
ferent in the two cell lines with CT26 cells less sensitive with respect to 4T1 cells (Fig. 3A,B) in which response to 
10 mM could not be documented for a complete loss of cell viability. Intriguingly, this drug action was enhanced 
by STS that further reduced FDG uptake under all experimental conditions in both cell lines (Fig. 3A,B) while 
synergism analysis confirmed that the two interventions acted on similar targets as suggested by the negative sign 
of their interaction mostly evident in CT26 line (Supplementary Figure 3A-B). By contrast, metabolic response of 
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Figure 1. MTF and STS effect on cancer growth and glucose metabolism. (A,B): cancer progression 
throughout the whole study period (14 days), respectively in CT26 and 4T1 mice. Average tumour volumes 
are expressed in cubic millimetres. White and black arrows correspond to PET1 and PET2 scans while dashed 
grey columns indicate STS. The effect of merged treatment on tumour growth was more powerful than each 
intervention alone in both cancer models leading to a profound reduction in cancer progression whose 
significance was reached at day 9 and further increased until day 14 with respect to controls. (C,D) represent 
MRGlu evaluation at PET1 (white columns) and PET2 (black columns). This parameter was significantly 
reduced by all treatments without significant difference between each intervention. The simultaneous evaluation 
of cancer volume and MRGlu through the total cancer glucose consumption analysis demonstrated an additive 
effect of MTF and STS on both CT26 (E) and 4T1 (F). Data are presented as mean ± SD. *p < 0.05; **p < 0.01 
(statistical differences vs controls). Black lines: statistical differences between each stressor at PET2).
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non-cancer cells (human fibroblasts) was completely different since both MTF (5 mM) and STS caused a signifi-
cant increase in FDG uptake (Supplementary Figure 2A).
To explain the mechanisms underlying the evident reduction in glucose avidity caused by both treatments 
in cancer cells, we first evaluated the availability of proteins related to glycolysis using a proteomic approach. 
The analysis was performed by Label Free Quantitation (LFQ) High Resolution/Mass Accuracy Liquid 
Chromatography Tandem Mass Spectrometry (HR/MA LC MS/MS), as described in detail in Supplementary 
Methods. Supplementary Figure 4A shows a representative heat map of selected Gene Ontology (GO) biological 
processes related to glycolysis. Interestingly, the two stressors induced a similar impairment in glucose metabo-
lism despite an opposite response of glycolytic enzymes asset that was depleted by STS and empowered by MTF.
Accordingly, we directly tested with Western blot analysis the key determinants of glycolytic flux in cancer. 
Expression of both GLUT1 (Fig. 3C) and HK II (Fig. 3D) did not explain FDG uptake response, since availabil-
ity of these proteins was reduced only by STS through a mechanism largely prevented by MTF (Supplementary 
Figure 3C-D). However, total cell lysate HK activity was similarly reduced in both cell lines by all tested protocols 
(Fig. 3E and Supplementary Figure 3E). Moreover, a completely different response was observed for lactate dehy-
drogenase (LDH, Fig. 3F) and for the rate-limiting steps of glycolysis catalysed by phosphofructokinase (PFK) 
and pyruvate kinase (PK) (Fig. 3G,H): the catalytic function of these enzymes was selectively impaired by STS 
being virtually not responsive to MTF (Supplementary Figure 3F-H) in both cancer models. Differently from 
MTF, whose action was similar in neoplastic and normal cells, STS effect on HK, PK and LDH activity was only 
trivial in fibroblasts (Supplementary Figure 2B-D).
Accordingly, the effect and the relative interactions of MTF and STS on cancer glycolytic rate were explained 
by the fact that the two interventions interfered with different targets of the same glycolytic pathway: MTF 
directly hampered HK II function while STS selectively impaired PFK and PK activity. The consequent reduc-
tion in glucose consumption was further enhanced by a relative de-localization of HK II away from the outer 
mitochondrial membrane that was documented by immunofluorescence analysis (Fig. 4). This response and 
the consequent loss of preferential access to ATP for glucose phosphorylation18 actually occurred under the two 
treatments and mostly under their combination.
Figure 2. Parametric maps of glucose consumption (MRGlu). Here is appreciable, at a glance, the effect of 
the different treatments on CT26 (upper panels) and 4T1 (bottom panels) cancer models. Both STS and MTF 
affected cancer metabolism and growth. The most evident effect was obtained under combined treatment, in 
which tumor progression between the two scans was virtually abolished.
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Figure 3. Effects of MTF and STS on the main regulators of glucose consumption. (A) After a modest 
increase at the lowest MTF dose (2.5 mM), FDG uptake in CT26 (white columns) progressively decreased down 
to its minimum value at 10 mM concentration. (B) In 4T1 cells (gray columns), tracer retention was already 
reduced at the lowest concentration (2.5 mM), while the effect of 10 mM dose could not be documented because 
cells viability was completely lost. In both CT26 and 4T1 cells the drug effect was empowered by STS (dashed 
columns) that reduced FDG uptake in all experimental conditions. (C,D) Western blot evaluation in CT26 cells 
demonstrated that GLUT1 and HK II expression were reduced only in presence of STS. (E) On the contrary, 
HK II function was significantly and similarly reduced by all tested protocols in both cell lines, reaching its 
lowest value under merged treatment. (F) LDH activity showed an almost exclusive response to STS. (G,H) STS 
induced a significant reduction of PFK and PK enzymatic activities in both cell lines, independently from MTF. 
Data are presented as mean ± SD; (*p < 0.05; **p < 0.01 statistical differences vs controls).
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Effect of metformin and starvation on cancer energy metabolism. The impairment in glyco-
lytic flux induced by MTF and STS was paralleled by a significant reduction in intracellular ATP concentration 
(Fig. 5A), by a marked increase in AMP (Fig. 5B) and thus by an obvious reduction in ATP/AMP ratio (Fig. 5C) 
in both models of colon and breast carcinoma. Again, combining the two treatments caused the most severe 
energy depletion, though with a negative interaction (Supplementary Figure 5A-C). This effect was only partially 
reproduced in fibroblasts (Supplementary Figure 2E).
The role of glycolysis as a common target of both interventions was confirmed by the evident response of 
glycolytic intermediates and end product. As shown in Fig. 5D, cytosol concentration of glucose-6-phosphate 
(G6P) moderately decreased under STS and fell down to its lowest values in response to MTF, confirming the role 
of HK II inhibition caused by the biguanide. On the contrary, lactate release in culture medium had a completely 
dissimilar behaviour: it was markedly increased by MTF and significantly reduced by STS (Fig. 5E) without any 
interaction between the two treatments (Supplementary Figure 5E).
This divergent response occurred despite a preserved availability of pyruvate whose cytosol concentration was 
increased by all interventions up to its maximal value under merged treatment (Fig. 5F, Supplementary Figure 5F). 
These data thus indicated that although both stressors actually acted on glycolytic rate, they determined a dif-
ferent fate of intracellular glucose within cancer cell: STS preserved its conversion to acetyl-CoA for Krebs cycle 
utilization, while MTF markedly increased its conversion to lactate. In other words, these experiments suggested 
that cell respiration was enhanced by STS and impaired by MTF.
To elucidate the mechanisms underlying the divergent fate of G6P we repeated a proteomic evaluation of 
major OXPHOS components (Supplementary Figure 4B). At this analysis, protein abundance of respiratory chain 
elements was reduced by STS and was increased by MTF despite the marked increase in lactate release induced 
by the biguanide. Evaluation of OXPHOS activity explained this apparent paradox. Actually, Complex I activity 
was virtually abolished by 5 mM MTF that also prevented the boost induced by STS (Fig. 6A). On the contrary, 
Complex IV was enhanced by STS while it was not influenced at all by MTF (Fig. 6B). Although Complex II 
function did not respond to either treatment, these divergent actions resulted in largely different functional con-
sequences (Supplementary Figure 6A-B). MTF virtually abolished oxygen consumption rate (OCR) blocking 
pathway I-III-IV (Fig. 6C and Supplementary Figure 6C). By contrast, STS markedly increased OCR enhancing 
both respiratory pathways with its effect persisting under merged treatment only on pathway II-III-IV (Fig. 6D 
and Supplementary Figure 6D). Again, STS appeared to selectively affect cancer cells since Complex IV function 
remained unchanged under all treatments in fibroblasts, while MTF action on Complex I was reproducible in all 
studied cells (Supplementary Figure 2F-G).
The consequences of this functional impairment were even more evident when energy balance was analysed. 
ATP synthesis through pathway I-III-IV was virtually abolished by MTF independently from STS (Fig. 6E, 
Supplementary Figure 6E). On the other hand, its production through pathway II-III-IV was significantly 
impaired by STS despite the increased OCR (Fig. 6F, Supplementary Figure 6F). The mechanisms underlying 
this mismatch was elucidated by the measurement of reactive oxygen species (ROS), whose production was 
Figure 4. Immunofluorescence analysis in CT26 cells. (A) Confocal microscopy for HK II and mitochondria 
in CT26 cells under control condition, STS, MTF 5 mM for 24 hours and under MTF + STS. Mitochondria were 
labeled by MitoTracker Far Red; HKII was stained by indirect immunofluorescence, using a FITC-conjugated 
secondary antibody. First, second and third rows show staining for HK II, mitochondria and both, respectively. 
Merge images (third row) document that STS and MTF caused a significant and selective dislocation of HK II 
from mitochondrial membrane to the cytosol, mostly evident under combined treatment. (B) Percentage of 
total HK II bound to mitochondria showed a progressive reduction under STS, MTF and combined treatment 
in both CT26 (white columns) and 4T1 cells (gray columns). Data are presented as mean ± SD; (*p < 0.05; 
**p < 0.01 statistical differences vs controls).
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enhanced by STS independently from MTF administration in both CT26 (Fig. 6G) and 4T1 (Fig. 6H) cell lines 
(Supplementary Figure 6G).
Accordingly, STS and MTF caused a severe depletion of cancer cell energy asset through different actions on 
mitochondrial respiratory chain: the former mostly uncoupled OXPHOS and ATP synthesis, the latter markedly 
and selectively impaired cell respiration through a severe inhibition of Complex I.
Cancer biological response to energy depletion caused by metformin and starvation. Since 
glucose consumption is critical for cancer cell survival and growth, we verified whether the profound impairment 
in cell energy asset and glycolytic rate did eventually hamper cell viability and proliferation. Actually, the effect of 
MTF and STS was confirmed by this analysis: MTF caused a cytotoxic effect that was amplified by STS in CT26 
(Fig. 7A) and mostly in 4T1 cells, in which massive cell death occurred under combined treatment already at 
5 mM MTF (Fig. 7B). Synergism analysis did not identify a statistically significant interaction. Finally, the reduc-
tion in cell viability was paralleled by a decrease in proliferation rate in both models of colon (Fig. 7C) and breast 
(Fig. 7D) carcinoma.
This biological response closely agreed with a down-regulation of pathways promoting cancer growth that 
were tested in CT26 cells. In fact, MTF markedly reduced PI3K expression (Fig. 7E) and AKT phosphorylation 
(Fig. 7F) with a further, though relatively modest, enhancement induced by STS (Fig. 7E,F) despite stable levels of 
phosphatase and tensin homolog (PTEN) under all study conditions (Fig. 7G). Again, synergism analysis did not 
identify a statistically significant interaction.
Discussion
The present study confirms the hypothesis that combining MTF and STS profoundly depletes cancer energy 
asset interfering with different steps of the same metabolic pathways: glycolysis and OXPHOS. This impairment 
Figure 5. Cancer cell energy asset and glycolytic pathways. (A) ATP content in CT26 (white columns) and 
4T1 (grey columns) cells was significantly reduced by STS, MTF and mostly by their combination. This effect 
was coupled by an increase in AMP concentration (B) and, thus, by an evident reduction in ATP/AMP ratio 
(C). The metabolic pathways of these findings are depicted below: (D) shows a significant reduction in G6P 
levels, mostly evident under MTF. This effect was paralleled by a significant increase in lactate release induced 
by the biguanide with an opposite response to STS (E). This different action was not explained by pyruvate 
availability whose concentration was increased by all interventions (F). Data are presented as mean ± SD; 
(* p < 0.05; ** p < 0.01 statistical differences vs controls).
www.nature.com/scientificreports/
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Figure 6. Effects of MTF and STS on OXPHOS and ROS production. (A) profound inhibition exerted by 
5 mM MTF and merged treatment on mitochondrial complex I activity in both CT26 (white columns) and 
4T1 (grey columns) cells. By contrast, STS led to an increase in Complex I and IV activity, independently from 
MTF (A–C). OCR response to pyruvate/malate administration (interrogating I-III-IV pathway) was virtually 
abolished after exposure to MTF and merged treatment while it was increased by STS alone. (D) STS slightly 
increased OCR response pathway II-III-IV activity as evaluated by succinate administration, independently 
from the presence of MTF. (E) ATP synthesis in the presence of pyruvate/malate was reduced by STS and 
virtually abolished by MTF and MTF + STS. (F) In the presence of succinate, ATP synthesis was slightly though 
significantly reduced by MTF and merged treatment. ROS production was enhanced by STS regardless MTF 
administration in both CT26 (G) and 4T1 (H) explaining the mismatch between increased OCR and reduced 
ATP synthesis. Data are presented as mean ± SD; (*p < 0.05; **p < 0.01 statistical differences vs controls).
www.nature.com/scientificreports/
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Figure 7. Cancer biological response to energy depletion. (A) In CT26, cell viability progressively decreased 
with increasing MTF doses. This response was further amplified by STS (dashed columns). (B) This effect was 
more evident in 4T1 cells in which the cytotoxicity of MTF + STS was already massive at 5 mM MTF. (C,D) 
Proliferation rate was reduced under each condition with a largely additive effect of MTF and STS, both in CT26 
(C) and 4T1 (D) cells. At Western blot evaluation in CT26 cells, STS, MTF and mostly merged treatment caused 
a decrease in PI3K (E) and pAKT expression (F) despite a stable expression of PTEN in all conditions (G). Data 
are presented as mean ± SD; (*p < 0.05; **p < 0.01 statistical differences vs controls).
www.nature.com/scientificreports/
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was particularly evident in cancer cells in which merged treatment caused an evident cytotoxic effect as well as a 
marked decrease of in vitro cell proliferation rate and in vivo tumour growth.
The interaction between the two interventions on FDG uptake resulted from the combined interference on 
different enzymes regulating glycolytic pathway: MTF hampered HK II function while STS affected catalytic 
activity of PFK and PK. A similar consideration applied to OXPHOS that offered different targets to each treat-
ment: MTF inhibited respiratory activity directly hampering Complex I function, while STS uncoupled electron 
transport chain and ATP synthase increasing ROS generation. As a result, cancer cells exposed to merge treat-
ment coupled massive energy depletion with a significant oxidative damage. The obvious consequence of this 
impairment was a significant cytotoxic effect associated with a reduction in proliferating rate in both colon and 
breast carcinoma.
In agreement with previous experience18,19, FDG uptake showed a dose-dependent decrease under MTF. This 
response was more evident in 4T1 than in CT26 cells and was further amplified by STS in both cell lines. The 
paradoxical reduction in glucose uptake occurred despite ATP depletion and was independent from variations in 
GLUT1 abundance. On the contrary, it was at least partially explained by an impaired glucose phosphorylation 
caused by MTF interference on HK II catalytic pocket18. The relevance of this effect was confirmed by both rela-
tive stability of enzyme availability and decrease in intra-cellular G6P concentration.
Differently from biguanide, STS down-regulated glucose consumption selectively interfering with the glyc-
olysis rate limiting step PFK and the downstream reaction catalysed by PK. This concept was confirmed by the 
observation that STS-induced block in downstream reactions prevented the MTF-induced decrease in G6P level 
and abolished the marked increase in lactate release caused by MTF alone. Besides this direct interference, both 
treatments impaired HK II activity with a further mechanism. The catalytic function of this enzyme is largely 
empowered by its p-AKT-dependent link with outer mitochondrial membrane20. In agreement with response 
of p-AKT, immunofluorescence analysis documented that both MTF and STS, and even more their association, 
prevented this mitochondrial binding and thus the direct enzyme access to mitochondrial ATP for glucose phos-
phorylation. Accordingly, HK II activity impairment was relatively underestimated by our enzymatic assays and 
largely contributed to the reduction in glycolytic flux21.
The most recognized cellular effect of MTF is related to its capability to hamper mitochondrial Complex I 
activity12,22. This drug action was largely confirmed in our study and implied a virtual OCR abolition through 
Complex I-III-IV pathway in both cancer cell lines. As an obvious consequence, MTF determined a severe reduc-
tion in cell energy asset and ATP synthesis. The decreased OXPHOS rate was coherent with the observed increase 
in glycolytic end product (lactate), whose extracellular release represents a basic physiological response to restore 
NADH oxidation to NAD+ as to maintain glycolytic flux23. By contrast, STS prevented this biguanide effect and 
decreased lactate release regardless MTF presence. This response was only partially explained by a concomitant 
down-regulation in LDH activity while it was coherent with the accelerated OCR induced by STS in both cell 
lines. On the other hand, the mismatch between increased OXPHOS rate and reduced ATP content was explained 
by the uncoupling of electron transport chain and ATP synthase function resulting in increased ROS generation 
and consequent mitochondrial membrane damage24,25. Interestingly, this response persisted virtually unmodified 
under MTF, confirming the contribution of Complex II to the oxidative damage26, besides the well-described role 
of Complexes I and III27,28.
The severe energy depletion associated with an accelerated ROS generation under merged treatment even-
tually resulted in a profound reduction in cancer cell proliferation and viability that closely agreed with the 
downregulation of PI3K-Akt pathway29. More importantly, the relevance of this direct metabolic effect was con-
firmed in vivo in which the virtual flattening of tumour growth curve was at least partially enhanced by the 
whole body adaptation to the metabolic action of both stressors. In agreement with previous experience, neither 
abolition of food intake during STS nor MTF treatment alone significantly affected serum glucose level that, 
instead, was significantly reduced only in mice exposed to merged treatment. This observation closely fits with 
the well-documented anti-diabetic action of biguanide that limits gluconeogenesis9,30 and impairs G6Pase activ-
ity in liver and kidney cells as to increase their glycogen content31 while decreasing glucose delivery into the 
bloodstream.
Actually, cancer metabolic response to the merged treatment tended to decrease over time and was less evident 
at PET#2 than one week after tumour implantation. However, this finding was largely apparent due to the contin-
uous nature of MTF administration as opposed to the transient application of STS, suggesting that the biguanide 
actually prevented the rebound phase of glucose consumption during re-feeding period. On the other hand, the 
marked reduction in lesion growth observed under merged treatment with respect to MTF alone, suggests the 
presence of further factors amplifying the anticancer potential besides the interference on glucose availability.
In this line, the possible therapeutic potential of combining MTF and STS was corroborated by several obser-
vations: on one hand, the selectivity of STS and MTF action on cancer cells was indicated by the opposite response 
of normal fibroblasts in which all interventions increased FDG uptake. On the other hand, the combined treat-
ment virtually abolished tumour growth and profoundly lessened total cancer glucose consumption in vivo being 
well tolerated in the whole group of 18 treated mice. Obviously, the high MTF dose needed and STS are difficult 
to extend to the clinical setting. However, the virtual abolition of cancer growth observed in mice supports the 
potential of targeting energy metabolism in cancer treatment. In this line, these data point out the need to identify 
specific ways to carry the drug directly into the lesion or molecules effective at lower concentration to improve 
therapy effectiveness.
Methods
Chemicals. MTF was provided by Sigma-Aldrich (St. Louis, MO, USA). FDG was produced according to 
standard methodology. Daily quality controls always documented adequate standards and, in particular, a radi-
ochemical purity ≥ 98%32.
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Animal Models. All animal experiments were reviewed and approved by the Licensing and Ethical 
Committee of our Institute and by the Italian Ministry of Health. six- weeks-old female BALB/c mice purchased 
from Charles River Laboratories (Lecco,,Italy), housed under specific pathogen-free conditions. The caloric 
content of the normal chow was distributed as 58% carbohydrate, 12% fat, and 30% protein, and normal food 
consumption was maintained during the whole experiments for all groups except for starved mice that inter-
rupted the normal diet twice before each PET studies for 48 hours. All animals were allowed free access to water. 
Metformin was orally administered by diluting the drug in autoclaved drinking water at a concentration of 3 mg/
mL according to a procedure approximately accounting for a dose of 750 mg/Kg/die19,33,34.
As a preliminary study, 2 × 105 CT26 colon cancer cells were inoculated subcutaneously in the dorsal hip of 
12 syngeneic mice that were followed without any other manoeuvre for four weeks under control conditions or 
under merged treatment. For the imaging study, inoculum was performed with the same number of either CT26 
or 4T1 cells.
Each model was subsequently divided into four groups of six animals: “control” group did not receive any 
treatment and were kept under standard conditions for the whole duration of the study; “STS” group were sub-
mitted to 48 hours STS (absence of food) before each imaging; “MTF” group received metformin treatment for 
the whole duration of the study and “MTF + STS” group received the combined treatment. Cancer volume was 
determined by using external caliper and tumor volume was calculated using the following equation: tumor 
volume (mm3) = (length × width × height) × π /6, expressing length, width and height in mm. Mice were euth-
anized by CO2 asphyxiation at the end of the study.
Experimental micro-PET scanning protocol. In vivo imaging was performed according to a protocol 
validated in our lab19,34. Mice were weighted and anesthesia was induced by intra-peritoneal administration of 
ketamine/xylazine (100 and 10 mg/kg, respectively). Serum glucose level was tested and animals were positioned 
on the bed of a dedicated micro-PET system (Albira, Carestream Inc, US) whose two-ring configuration permits 
to cover the whole animal body in a single bed position. A dose of 3–4 MBq of FDG was then injected through a 
tail vein, soon after start of a list mode acquisition lasting 50 minutes.
Image processing. Acquisition was reconstructed using the following framing rate: 10 ×  15 secs, 
5 − × 30 secs, 2 × 150 secs, 6 × 300 secs, 1 × 600 secs). PET data were reconstructed using a maximal likelihood 
expectation maximization method (MLEM). An experienced observer, unaware of the experimental type of ana-
lyzed mouse, identified a volume of interest (VOI) in the left ventricular chamber. Then, the computer was asked 
to plot the time-concentration curve within this VOI throughout the whole acquisition to define tracer input 
function. Whole body FDG clearance (in ml × min-1) was calculated using the conventional stochastic approach 
as the ratio between injected dose and integral of input function from 0 to infinity, fitting the last 20 minutes with 
a mono-exponential function35. Further VOIs were drawn over cancer lesions to measure maximal standardized 
uptake value (SUV), i.e. the most commonly accepted index of tissue FDG uptake, expressed as the fraction of 
injected tracer dose normalized for body weight.
Cancer and normal tissues glucose consumption (metabolic rate of glucose - MRGlu) was expressed in nM 
X min-1 X g-1 and was estimated in these last VOIs according to Gjedde-Patlak36 graphical analysis by using the 
routine of a dedicated software (PMOD, Zurich, Switzerland). Briefly, the software utilizes the input function to 
transform the original tissue activity measurements by fitting the data in each voxel with the slope of the regres-
sion line defined by the model. In all cases, lumped constant value was set at 1.
Cell lines and culture conditions. CT26, 4T1 and human fibroblasts, were purchased from ATCC (LGC 
Standards S.r.l., Milan, Italy) and cultured in DMEM medium (Invitrogen, Monza, Italy) containing 2 g/l glu-
cose and supplemented with 1% L-glutamine, penicillin/streptomycin, nonessential amino acids and 10% fetal 
bovine serum (FBS) (all from Sigma Aldrich, Milan, Italy). All treatments were performed at 37 °C under 5% CO2. 
Short-term starvation (STS) consists in glucose and in serum restriction obtained by culturing the cells in DMEM 
medium containing 0.5 g/l glucose and 1% FBS for 48 hours. MTF incubation was performed with different drug 
concentrations (2,5; 5 and 10 mM) for 24 and 48 hours, in combination or not with STS.
FDG Uptake Evaluathion. Labeling was performed incubating 106 cells with FDG according to a proce-
dure validated in our laboratory18. Immediately before the experiment, glucose free medium was added with 
two mL PBS containing FDG at a concentration of 37 KBq/mL. Tracer exposure was maintained for 60 minutes 
at 37 °C. Thereafter, uptake process was stopped by adding 4 ml of PBS before centrifugation at 450 g for 10 min. 
Supernatant was removed and cell pellet re-suspended in 1 ml of saline buffer. Free and bound activities were thus 
simultaneously counted using a Packard Cobra II gamma counter (Packard, Meriden, CT) with a 10% energy 
window centered at 511 KeV. FDG retention was measured as the ratio between bound and total radioactivity. In 
all cases, labeling procedure did not affect cell viability as documented by trypan blue staining.
Proteomic analysis. Cellular peptides were prepared as described in details in supplementary section. The 
samples in the different experimental conditions were analyzed by liquid chromatografy-tandem mass spectrom-
etry (LC-MS/MS). Raw mass spectrometric data were analyzed with the MaxQuant software (version 1.4.1.2)37.
Western blotting. Western blot experiments were performed accordingly to the standard procedure38. 
We tested the following antibodies: anti-GLUT1, anti-HKII, anti-PI3K (Cell Signaling), anti-PTEN (Millipore), 
anti-Phospho-AKT (Ser473) and anti-β -actin (Cell Signaling).
Spectrophotometric enzymes assay. Hexokinase (HK), Phosphofructokinase (PFK), glucose 6 phos-
phate (G6P), pyruvate kinase (PK) and lactic dehydrogenase (LDH) were assayed spectrophotometrically in a 
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double beam spectrophotometer (UNICAM UV2, Analytical S.n.c., Italy) as previously described18. The activity 
assay of the four redox Complexes in the CT26 and 4T1 cells were measured on 50 μ g of total protein as described 
in the supplementary methods paragraph.
Co-localization experiments. Intracellular localization of HK was studied on cells cultured on glass cov-
erslips and treated with MitoTracker probe (Life Technologies Ltd, Monza MB, Italy), rabbit anti-HKII (C64G5) 
(primary antibodies (Euroclone) and then with a goat anti-Rabbit Alexa Fluor 488 secondary antibody (Molecular 
Probes Eugene, OR, USA). Results were analyzed using an Olympus (Olympus Optical) laser-scanning micro-
scope FV500 equipped with an Olympus IX81 inverted microscope and Argon ion 488 nm, He-Ne 543 nm, and 
He-Ne 633 nm lasers. Digital images were acquired through a PLAPO 60 × objective, with the Fluoview 4.3b soft-
ware program. Images were acquired sequentially as single transcellular optical sections. Spatial co-localization 
was analyzed by Image J 1.34f software (NIH).
Evaluation of ATP concentration. ATP concentration was measured in a luminometer (Lumi-Scint, 
Bioscan) by the luciferin/luciferase chemiluminescent method. The reactions employed are described in supple-
mentary methods.
Oxygraphic measurements, and ROS production. O2 consumption was measured using a thermo-
statically controlled oxygraph apparatus equipped with amperometric electrode (Microrespiration, Unisense A/S, 
Århus, Denmark) as described in supplementary section.
ROS production was evaluated by 2′ , 7′ –dichlorofluorescein diacetate (DCFDA, Invitrogen) staining and 
acquisition/ analysis in a Gallios cytometer (Becton Dickinson).
Cell viability and proliferation. Cell viability was evaluated by Trypan blue (Sigma Aldrich) exclusion 
test. To asses proliferation, cancer cells were labeled with 20 μ M CarboxyfluoresceinSuccinimidyl ester (CFSE) 
(InVitrogen) following the manufacture’s instructions. Samples were acquired in a Gallios cytometer and analysed 
using Kaluza software.
Statistical analysis. The data are presented as mean ± standard deviation (SD). For comparison between 
different groups, the Null hypothesis was tested by analysis of variance (ANOVA) for multiple groups. Synergism 
was tested using factorial experiment design in which the interaction factor was tested using the univariate anal-
ysis of the general linear regression model as described by Slinker39. Statistical significance was considered for 
p values p < 0.05. All analyses were performed using SPSS software package, 20.0.0 release (IBM, Armonk, NY)
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